Remyelination

Clene Presents Phase 2 CNM-Au8 CNS Target Engagement Data at the International Parkinson and Movement Disorder Society Virtual Congress 2021

Friday, September 17, 2021 - 12:00pm

Clenes Phase 2 REPAIR program achieved a statistically significant increase in its primary endpoint, the mean change in brain NAD+/NADH ratio (p=0.037).

Key Points: 
  • Clenes Phase 2 REPAIR program achieved a statistically significant increase in its primary endpoint, the mean change in brain NAD+/NADH ratio (p=0.037).
  • In the REPAIR-PD study, the trend in NAD+/NADH ratio improvement was driven by both increased NAD+ and decreased NADH.
  • Robert Glanzman, MD FAAN, Clenes Chief Medical Officer, commented, We are very pleased to share our results with the Parkinsons treatment community at the MDS Virtual Congress.
  • The International Parkinson and Movement Disorder Society (MDS) is a professional society of more than 11,000 clinicians, scientists and other healthcare professionals dedicated to improving the care of patients with movement disorders through education and research.

Encode Ideas, L.P. Announces the Initiation of Research Coverage on NervGen Pharma Corp.

Monday, September 13, 2021 - 2:00pm

Dover, Delaware--(Newsfile Corp. - September 13, 2021) - Encode Ideas, L.P. Initiates Research on NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF).

Key Points: 
  • Dover, Delaware--(Newsfile Corp. - September 13, 2021) - Encode Ideas, L.P. Initiates Research on NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF).
  • Encode Ideas, L.P., a healthcare focused research firm, announced today it is initiating coverage on NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF).
  • Encode Ideas, L.P. is a healthcare focused research firm, founded in 2019, providing institutional quality research and investment ideas.
  • Encode Ideas, L.P. has been retained by NervGen, Inc. to provide investor awareness and research coverage.

Clene Completes Final Patient Visit in Phase 2 RESCUE-ALS Study: Topline Data Readout Expected Q4 2021

Thursday, September 9, 2021 - 12:00pm

The trial enrolled a total of 45 patients with ALS, with unblinded topline data expected in Q4 2021.

Key Points: 
  • The trial enrolled a total of 45 patients with ALS, with unblinded topline data expected in Q4 2021.
  • Thus far the blinded interim data we have seen on the primary and secondary endpoints of our RESCUE-ALS study are very encouraging.
  • We look forward to the unblinded topline readout before the end of the year.
  • Interim blinded efficacy results from the Phase 2 RESCUE-ALS study were presented at the ENCALS 2021 Annual Meeting on May 12, 2021.

Autobahn Therapeutics Acquires Clinical-Stage FAAH Inhibitor from Astellas, Strengthening its Brain Targeting Chemistry Platform

Tuesday, May 11, 2021 - 1:30pm

Peripheral blockade of FAAH activity further improves selective brain delivery of Autobahn\xe2\x80\x99s compounds and enhances the ability to tailor a drug\xe2\x80\x99s biodistribution to match the pathophysiology of various disorders.

Key Points: 
  • Peripheral blockade of FAAH activity further improves selective brain delivery of Autobahn\xe2\x80\x99s compounds and enhances the ability to tailor a drug\xe2\x80\x99s biodistribution to match the pathophysiology of various disorders.
  • \xe2\x80\x9cWhile there have been numerous advancements in the care of patients with MS, we believe there is a tremendous need for new therapeutic agents targeting remyelination.
  • Autobahn has acquired global intellectual property, development and regulatory rights to ASP3652.\nAutobahn Therapeutics is focused on restoring hope for people affected by CNS disorders.
  • Autobahn is leveraging its brain-targeting chemistry platform to unlock new therapeutic opportunities through precision tuning of the central exposure of its molecules.

Pipeline Therapeutics to Participate in the 2020 RBC Capital Markets and SVB Leerink Private Company Conferences

Tuesday, December 8, 2020 - 4:00pm

Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the company will participate in two upcoming investor conferences in December.

Key Points: 
  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the company will participate in two upcoming investor conferences in December.
  • Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair.
  • The company's lead clinical program, PIPE-505, is currently enrolling patients in a phase 1/2a study to treat sensorineural hearing loss (SNHL) associated with speech-in-noise disability.
  • The company also has a portfolio of programs addressing a range of neurological disorders, including development candidate PIPE-307 which is focused on remyelination to treat multiple sclerosis.

Pipeline Therapeutics to Present at Stifel 2020 Virtual Healthcare Conference

Thursday, November 12, 2020 - 4:00pm

Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that Carmine Stengone, President and Chief Executive Officer, will present at the Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, at 2:00 p.m.

Key Points: 
  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that Carmine Stengone, President and Chief Executive Officer, will present at the Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, at 2:00 p.m.
  • Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair.
  • The company's lead clinical program, PIPE-505, is currently enrolling patients in a phase 1/2a study to treat sensorineural hearing loss (SNHL) associated with speech-in-noise disability.
  • The company also has a portfolio of programs addressing a range of neurological disorders, including development candidate PIPE-307 which is focused on remyelination to treat multiple sclerosis.

Pipeline Therapeutics to Present at BMO’s Fall Private Company Showcase 2020

Thursday, October 8, 2020 - 4:00pm

Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that Carmine Stengone, President and Chief Executive Officer, will present at the Fall Private Company Showcase 2020, co-hosted by BMO, a fully virtual management access conference, on Thursday, October 15, at 1:40 p.m.

Key Points: 
  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced that Carmine Stengone, President and Chief Executive Officer, will present at the Fall Private Company Showcase 2020, co-hosted by BMO, a fully virtual management access conference, on Thursday, October 15, at 1:40 p.m.
  • Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair.
  • The company's lead clinical program, PIPE-505, is currently enrolling patients in a phase 1/2a study to treat sensorineural hearing loss (SNHL) associated with speech-in-noise disability.
  • The company also has a portfolio of programs addressing a range of neurological disorders, including development candidate PIPE-307 which is focused on remyelination to treat multiple sclerosis.

Pipeline Therapeutics to Present at Two Upcoming Investor Conferences

Wednesday, September 9, 2020 - 4:00pm

Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the company will participate in two upcoming investor conferences in September.

Key Points: 
  • Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the company will participate in two upcoming investor conferences in September.
  • Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair.
  • The company's lead clinical program, PIPE-505, is currently enrolling patients in a phase 1/2a study to treat sensorineural hearing loss (SNHL) associated with speech-in-noise disability.
  • The company also has a portfolio of programs addressing a range of neurological disorders, including development candidate PIPE-307 which is focused on remyelination to treat multiple sclerosis.

Rewind Therapeutics appoints Biopharmaceutical Industry Veteran Kees Been as Non-Executive Director

Wednesday, September 2, 2020 - 8:00am

LEUVEN, Belgium, Sept. 2, 2020 /PRNewswire/ -- Rewind Therapeutics ("Rewind"), a private Belgian biotech company developing innovative first-in-class remyelinating therapies for myelin-related diseases such as multiple sclerosis, is delighted to announce the appointment of Kees Been to its Board of Directors as a Non-Executive Director.

Key Points: 
  • LEUVEN, Belgium, Sept. 2, 2020 /PRNewswire/ -- Rewind Therapeutics ("Rewind"), a private Belgian biotech company developing innovative first-in-class remyelinating therapies for myelin-related diseases such as multiple sclerosis, is delighted to announce the appointment of Kees Been to its Board of Directors as a Non-Executive Director.
  • "I am delighted to welcome Kees to the Board," said Jim Van heusden, Executive Chairman of Rewind Therapeutics.
  • "Kees brings vast experience in the discovery and advancement of novel neuroscience drug candidates and in growing emerging biotech businesses.
  • Kees Been added: "Rewind has a truly novel approach to tackling some very serious and debilitating neurological diseases through remyelination of affected nerves.

Rewind Therapeutics appoints Biopharmaceutical Industry Veteran Kees Been as Non-Executive Director

Wednesday, September 2, 2020 - 8:00am

LEUVEN, Belgium, Sept. 2, 2020 /PRNewswire/ -- Rewind Therapeutics ("Rewind"), a private Belgian biotech company developing innovative first-in-class remyelinating therapies for myelin-related diseases such as multiple sclerosis, is delighted to announce the appointment of Kees Been to its Board of Directors as a Non-Executive Director.

Key Points: 
  • LEUVEN, Belgium, Sept. 2, 2020 /PRNewswire/ -- Rewind Therapeutics ("Rewind"), a private Belgian biotech company developing innovative first-in-class remyelinating therapies for myelin-related diseases such as multiple sclerosis, is delighted to announce the appointment of Kees Been to its Board of Directors as a Non-Executive Director.
  • "I am delighted to welcome Kees to the Board," said Jim Van heusden, Executive Chairman of Rewind Therapeutics.
  • "Kees brings vast experience in the discovery and advancement of novel neuroscience drug candidates and in growing emerging biotech businesses.
  • Kees Been added: "Rewind has a truly novel approach to tackling some very serious and debilitating neurological diseases through remyelination of affected nerves.